221 related articles for article (PubMed ID: 27269942)
21. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
22. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
24. Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Vergote IB; Chekerov R; Amant F; Harter P; Casado A; Emerich J; Bauknecht T; Mansouri K; Myrand SP; Nguyen TS; Shi P; Sehouli J
J Clin Oncol; 2013 Sep; 31(25):3127-32. PubMed ID: 23897968
[TBL] [Abstract][Full Text] [Related]
25. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2011 Oct; (10):CD007927. PubMed ID: 21975775
[TBL] [Abstract][Full Text] [Related]
27. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
[TBL] [Abstract][Full Text] [Related]
28. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Konecny GE; Hendrickson AEW; Davidson TM; Winterhoff BJ; Ma S; Mahner S; Sehouli J; Fasching PA; Feisel-Schwickardi G; Poelcher M; Roman LD; Rody A; Karlan BY; Mullany SA; Chen H; Ray-Coquard IL; Provencher DM; Yachnin A; Cottu PH; Glaspy JA; Haluska P; Slamon DJ
Gynecol Oncol; 2021 Dec; 163(3):465-472. PubMed ID: 34642026
[TBL] [Abstract][Full Text] [Related]
29. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
30. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
31. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
[TBL] [Abstract][Full Text] [Related]
33. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Karlan BY; Oza AM; Richardson GE; Provencher DM; Hansen VL; Buck M; Chambers SK; Ghatage P; Pippitt CH; Brown JV; Covens A; Nagarkar RV; Davy M; Leath CA; Nguyen H; Stepan DE; Weinreich DM; Tassoudji M; Sun YN; Vergote IB
J Clin Oncol; 2012 Feb; 30(4):362-71. PubMed ID: 22184370
[TBL] [Abstract][Full Text] [Related]
34. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Ray-Coquard I; Cibula D; Mirza MR; Reuss A; Ricci C; Colombo N; Koch H; Goffin F; González-Martin A; Ottevanger PB; Baumann K; Bjørge L; Lesoin A; Burges A; Rosenberg P; Gropp-Meier M; Harrela M; Harter P; Frenel JS; Minarik T; Pisano C; Hasenburg A; Merger M; du Bois A;
Int J Cancer; 2020 Jan; 146(2):439-448. PubMed ID: 31381147
[TBL] [Abstract][Full Text] [Related]
35. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
37. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
[TBL] [Abstract][Full Text] [Related]
38. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
39. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
